$SLNO has generated 22 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on September 16, 2025. Adam Feuerstein (@adamfeuerstein) accounts for all but 2 of these mentions, establishing himself as the dominant voice discussing Soleno Therapeutics. The biotech category dominates discussion of this ticker, reflecting the company's therapeutic focus.

Neurocrine Biosciences announced an acquisition of $SLNO at $53.00 per share in an all-cash transaction valued at approximately $2.7 billion, with the deal expected to close in July 2026. A tender offer was commenced on April 20, 2026, set to expire on May 15, 2026. Feuerstein characterized the transaction as favorable to shareholders given Vykat's safety vulnerabilities and the limited negotiating position Soleno held. Special Situation Investments (@ssi_invest) tracked the deal progression through its merger arbitrage updates.